PDCD1 and neoplasm: PD-1 inhibitors have shown notable clinical success, both as monotherapy in patients with a PD-1 tumor proportion score (TPS) ≥50% and as part of combination therapies with chemotherapy, irrespective of PD-1 expression levels (5–7).